Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Third-party donor-derived virus- and fungus-specific T-lymphocytes
- Development stage
- Unknown
- Lead developer
- Westmead Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
An investigational adoptive cellular immunotherapy consisting of HLA-matched, third-party donor-derived T-lymphocytes specific for multiple viral and fungal pathogens. Developed by the University of Sydney and Westmead Hospital, the therapy targets cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, as well as fungal species including *Aspergillus* and *Candida*. The T-cells are expanded from healthy donor apheresis products using activation markers like CD137 to select for pathogen-specific populations. It is intended for the treatment of refractory infections in patients following allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). The therapy aims to restore cellular immunity against common opportunistic pathogens in immunocompromised individuals.
- Other names
- Multi-pathogen specific T-cellsVirus- and fungus-specific T-lymphocytesVSTsHLA-matched third-party donor-derived CTLs
02
Targets
GR (Glucocorticoid receptor)Pathogen-derived peptide-human leukocyte antigen complexesCrf1/p41-HLA (Cross-reactive fungal peptide-HLA complexes shared between Aspergillus and Candida)MiHA (Minor histocompatibility antigen)
Beyond the preview
Go deeper on Third-party donor-derived virus- and fungus-specific T-lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Third-party donor-derived virus- and fungus-specific T-lymphocytes.